 Kathleen Bickel
Concepts (95)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Palliative Care | 6 | 2022 | 815 | 0.920 |
Why?
| | Terminal Care | 4 | 2019 | 246 | 0.780 |
Why?
| | Neoplasms | 7 | 2023 | 2703 | 0.630 |
Why?
| | Cost-Benefit Analysis | 1 | 2017 | 605 | 0.430 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2019 | 848 | 0.360 |
Why?
| | Quality of Life | 3 | 2023 | 2954 | 0.320 |
Why?
| | Bodily Secretions | 1 | 2008 | 2 | 0.300 |
Why?
| | Mouth | 1 | 2008 | 87 | 0.280 |
Why?
| | Veterans | 1 | 2019 | 1479 | 0.280 |
Why?
| | Respiratory Sounds | 1 | 2008 | 109 | 0.280 |
Why?
| | Death | 1 | 2008 | 124 | 0.270 |
Why?
| | Oncologists | 2 | 2016 | 43 | 0.240 |
Why?
| | Advance Care Planning | 2 | 2020 | 221 | 0.230 |
Why?
| | Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2024 | 35 | 0.220 |
Why?
| | Ion Channel Gating | 1 | 2024 | 91 | 0.210 |
Why?
| | Advance Directives | 2 | 2023 | 81 | 0.210 |
Why?
| | Cryoelectron Microscopy | 1 | 2024 | 190 | 0.200 |
Why?
| | Medical Oncology | 2 | 2023 | 304 | 0.180 |
Why?
| | Living Wills | 1 | 2020 | 8 | 0.170 |
Why?
| | Hospice Care | 1 | 2023 | 201 | 0.160 |
Why?
| | Emergency Medicine | 1 | 2022 | 237 | 0.150 |
Why?
| | Decision Making | 2 | 2017 | 946 | 0.150 |
Why?
| | Hospice and Palliative Care Nursing | 1 | 2020 | 87 | 0.150 |
Why?
| | Suicide, Assisted | 1 | 2017 | 26 | 0.130 |
Why?
| | Low Back Pain | 1 | 2017 | 106 | 0.120 |
Why?
| | Informed Consent | 1 | 2017 | 188 | 0.120 |
Why?
| | Psychology | 1 | 2016 | 87 | 0.120 |
Why?
| | Culture | 1 | 2016 | 131 | 0.120 |
Why?
| | United States Department of Veterans Affairs | 1 | 2019 | 684 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 375 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 373 | 0.110 |
Why?
| | Adaptation, Psychological | 1 | 2020 | 672 | 0.110 |
Why?
| | Humans | 17 | 2024 | 139062 | 0.110 |
Why?
| | Physician-Patient Relations | 2 | 2016 | 582 | 0.110 |
Why?
| | Pandemics | 2 | 2020 | 1650 | 0.110 |
Why?
| | Continuity of Patient Care | 1 | 2016 | 284 | 0.100 |
Why?
| | Home Care Services | 1 | 2017 | 259 | 0.100 |
Why?
| | Physicians | 1 | 2022 | 929 | 0.100 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 335 | 0.100 |
Why?
| | Patient Acceptance of Health Care | 1 | 2019 | 854 | 0.100 |
Why?
| | Patient Education as Topic | 1 | 2017 | 763 | 0.090 |
Why?
| | Societies, Medical | 1 | 2016 | 839 | 0.090 |
Why?
| | Quality Improvement | 1 | 2020 | 1202 | 0.090 |
Why?
| | Attitude of Health Personnel | 2 | 2016 | 1159 | 0.090 |
Why?
| | Quality of Health Care | 1 | 2016 | 654 | 0.090 |
Why?
| | Hospitalization | 1 | 2020 | 2223 | 0.080 |
Why?
| | United States | 4 | 2020 | 15065 | 0.080 |
Why?
| | Clinical Competence | 1 | 2017 | 1140 | 0.080 |
Why?
| | Muscarinic Antagonists | 1 | 2008 | 30 | 0.070 |
Why?
| | Caregivers | 1 | 2016 | 905 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1550 | 0.070 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 1315 | 0.070 |
Why?
| | Aged | 4 | 2019 | 24236 | 0.060 |
Why?
| | Breast Neoplasms | 1 | 2017 | 2294 | 0.050 |
Why?
| | Membrane Potentials | 1 | 2024 | 282 | 0.050 |
Why?
| | Topoisomerase I Inhibitors | 1 | 2003 | 16 | 0.050 |
Why?
| | Potassium Channels | 1 | 2024 | 148 | 0.050 |
Why?
| | Topoisomerase II Inhibitors | 1 | 2003 | 26 | 0.050 |
Why?
| | Camptothecin | 1 | 2003 | 122 | 0.050 |
Why?
| | Forecasting | 1 | 2022 | 387 | 0.040 |
Why?
| | Social Work | 1 | 2020 | 86 | 0.040 |
Why?
| | Patient Care Planning | 1 | 2020 | 151 | 0.040 |
Why?
| | Models, Molecular | 1 | 2024 | 1598 | 0.040 |
Why?
| | Goals | 1 | 2020 | 174 | 0.040 |
Why?
| | Consensus | 1 | 2022 | 679 | 0.040 |
Why?
| | Research Personnel | 1 | 2020 | 184 | 0.040 |
Why?
| | Medical Assistance | 1 | 2017 | 14 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 275 | 0.030 |
Why?
| | Fellowships and Scholarships | 1 | 2020 | 311 | 0.030 |
Why?
| | Publication Bias | 1 | 2017 | 41 | 0.030 |
Why?
| | Canada | 1 | 2017 | 412 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2017 | 215 | 0.030 |
Why?
| | Patient Preference | 1 | 2016 | 197 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1084 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2003 | 1748 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2017 | 1380 | 0.020 |
Why?
| | Interviews as Topic | 1 | 2016 | 806 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2020 | 1088 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2017 | 799 | 0.020 |
Why?
| | Female | 5 | 2020 | 74074 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2017 | 1516 | 0.020 |
Why?
| | Qualitative Research | 1 | 2016 | 1445 | 0.020 |
Why?
| | Male | 4 | 2020 | 68324 | 0.020 |
Why?
| | Middle Aged | 3 | 2016 | 33864 | 0.020 |
Why?
| | Adult | 3 | 2016 | 38389 | 0.020 |
Why?
| | DNA Topoisomerases, Type I | 1 | 2003 | 15 | 0.010 |
Why?
| | DNA Topoisomerases, Type II | 1 | 2003 | 45 | 0.010 |
Why?
| | Etoposide | 1 | 2003 | 162 | 0.010 |
Why?
| | Maximum Tolerated Dose | 1 | 2003 | 204 | 0.010 |
Why?
| | Area Under Curve | 1 | 2003 | 315 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2017 | 10961 | 0.010 |
Why?
| | Cisplatin | 1 | 2003 | 327 | 0.010 |
Why?
| | Antigens, Neoplasm | 1 | 2003 | 317 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2003 | 1478 | 0.010 |
Why?
| | Cohort Studies | 1 | 2003 | 5736 | 0.010 |
Why?
|
|
Bickel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|